Literature DB >> 24170862

Region-specific restoration of striatal synaptic plasticity by dopamine grafts in experimental parkinsonism.

Daniella Rylander1, Vincenza Bagetta, Valentina Pendolino, Elisa Zianni, Shane Grealish, Fabrizio Gardoni, Monica Di Luca, Paolo Calabresi, M Angela Cenci, Barbara Picconi.   

Abstract

Intrastriatal transplantation of dopaminergic neurons can restore striatal dopamine levels and improve parkinsonian deficits, but the mechanisms underlying these effects are poorly understood. Here, we show that transplants of dopamine neurons partially restore activity-dependent synaptic plasticity in the host striatal neurons. We evaluated synaptic plasticity in regions distal or proximal to the transplant (i.e., dorsolateral and ventrolateral striatum) and compared the effects of dopamine- and serotonin-enriched grafts using a rat model of Parkinson disease. Naïve rats showed comparable intrinsic membrane properties in the two subregions but distinct patterns of long-term synaptic plasticity. The ventrolateral striatum showed long-term potentiation using the same protocol that elicited long-term depression in the dorsolateral striatum. The long-term potentiation was linked to higher expression of postsynaptic AMPA and N2B NMDA subunits (GluN2B) and was dependent on the activation of GluN2A and GluN2B subunits and the D1 dopamine receptor. In both regions, the synaptic plasticity was abolished after a severe dopamine depletion and could not be restored by grafted serotonergic neurons. Solely, dopamine-enriched grafts could restore the long-term potentiation and partially restore motor deficits in the rats. The restoration could only be seen close to the graft, in the ventrolateral striatum where the graft-derived reinnervation was denser, compared with the distal dorsolateral region. These data provide proof of concept that dopamine-enriched transplants are able to functionally integrate into the host brain and restore deficits in striatal synaptic plasticity after experimental parkinsonism. The region-specific restoration might impose limitations in symptomatic improvement following neural transplantation.

Entities:  

Keywords:  5-HT; 6-OHDA lesion; DA; LTD; LTP

Mesh:

Substances:

Year:  2013        PMID: 24170862      PMCID: PMC3831970          DOI: 10.1073/pnas.1311187110

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  75 in total

Review 1.  Putting a spin on the dorsal-ventral divide of the striatum.

Authors:  Pieter Voorn; Louk J M J Vanderschuren; Henk J Groenewegen; Trevor W Robbins; Cyriel M A Pennartz
Journal:  Trends Neurosci       Date:  2004-08       Impact factor: 13.837

2.  Focal not widespread grafts induce novel dyskinetic behavior in parkinsonian rats.

Authors:  Eleonora Maries; Jeffrey H Kordower; Yaping Chu; Timothy J Collier; Caryl E Sortwell; Eliza Olaru; Kathleen Shannon; Kathy Steece-Collier
Journal:  Neurobiol Dis       Date:  2005-08-10       Impact factor: 5.996

3.  Time-course of recovery of dopamine neuron activity during reinnervation of the denervated striatum by fetal mesencephalic grafts as assessed by in vivo voltammetry.

Authors:  C Forni; P Brundin; R E Strecker; S el Ganouni; A Björklund; A Nieoullon
Journal:  Exp Brain Res       Date:  1989       Impact factor: 1.972

4.  The A9 dopamine neuron component in grafts of ventral mesencephalon is an important determinant for recovery of motor function in a rat model of Parkinson's disease.

Authors:  Shane Grealish; Marie E Jönsson; Meng Li; Deniz Kirik; Anders Björklund; Lachlan H Thompson
Journal:  Brain       Date:  2010-01-31       Impact factor: 13.501

5.  Spatiotemporal pattern of striatal ERK1/2 phosphorylation in a rat model of L-DOPA-induced dyskinesia and the role of dopamine D1 receptors.

Authors:  Jenny E Westin; Linda Vercammen; Elissa M Strome; Christine Konradi; M Angela Cenci
Journal:  Biol Psychiatry       Date:  2007-07-26       Impact factor: 13.382

6.  Bilateral fetal mesencephalic grafting in two patients with parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)

Authors:  H Widner; J Tetrud; S Rehncrona; B Snow; P Brundin; B Gustavii; A Björklund; O Lindvall; J W Langston
Journal:  N Engl J Med       Date:  1992-11-26       Impact factor: 91.245

Review 7.  Dopamine-mediated regulation of corticostriatal synaptic plasticity.

Authors:  Paolo Calabresi; Barbara Picconi; Alessandro Tozzi; Massimiliano Di Filippo
Journal:  Trends Neurosci       Date:  2007-03-23       Impact factor: 13.837

Review 8.  Prospects of stem cell therapy for replacing dopamine neurons in Parkinson's disease.

Authors:  Olle Lindvall; Zaal Kokaia
Journal:  Trends Pharmacol Sci       Date:  2009-04-09       Impact factor: 14.819

9.  Neuropeptide messenger RNA expression in the 6-hydroxydopamine-lesioned rat striatum reinnervated by fetal dopaminergic transplants: differential effects of the grafts on preproenkephalin, preprotachykinin and prodynorphin messenger RNA levels.

Authors:  M A Cenci; K Campbell; A Björklund
Journal:  Neuroscience       Date:  1993-11       Impact factor: 3.590

10.  NR2B subunit exerts a critical role in postischemic synaptic plasticity.

Authors:  Barbara Picconi; Anna Tortiglione; Ilaria Barone; Diego Centonze; Fabrizio Gardoni; Paolo Gubellini; Paola Bonsi; Antonio Pisani; Giorgio Bernardi; Monica Di Luca; Paolo Calabresi
Journal:  Stroke       Date:  2006-06-01       Impact factor: 7.914

View more
  10 in total

1.  Optogenetics enables functional analysis of human embryonic stem cell-derived grafts in a Parkinson's disease model.

Authors:  Julius A Steinbeck; Se Joon Choi; Ana Mrejeru; Yosif Ganat; Karl Deisseroth; David Sulzer; Eugene V Mosharov; Lorenz Studer
Journal:  Nat Biotechnol       Date:  2015-01-12       Impact factor: 54.908

2.  Effects of Rho Kinase Inhibitors on Grafts of Dopaminergic Cell Precursors in a Rat Model of Parkinson's Disease.

Authors:  Jannette Rodriguez-Pallares; Ana I Rodriguez-Perez; Ana Muñoz; Juan A Parga; Juan J Toledo-Aral; Jose L Labandeira-Garcia
Journal:  Stem Cells Transl Med       Date:  2016-04-13       Impact factor: 6.940

Review 3.  Striatal Plasticity in L-DOPA- and Graft-Induced Dyskinesia; The Common Link?

Authors:  Daniella Rylander Ottosson; Emma Lane
Journal:  Front Cell Neurosci       Date:  2016-02-08       Impact factor: 5.505

Review 4.  On the neuronal circuitry mediating L-DOPA-induced dyskinesia.

Authors:  M Angela Cenci; Henrik Jörntell; Per Petersson
Journal:  J Neural Transm (Vienna)       Date:  2018-04-27       Impact factor: 3.575

Review 5.  Direct reprogramming into interneurons: potential for brain repair.

Authors:  Maria Pereira; Marcella Birtele; Daniella Rylander Ottosson
Journal:  Cell Mol Life Sci       Date:  2019-06-27       Impact factor: 9.261

Review 6.  Neuromodulators and Long-Term Synaptic Plasticity in Learning and Memory: A Steered-Glutamatergic Perspective.

Authors:  Amjad H Bazzari; H Rheinallt Parri
Journal:  Brain Sci       Date:  2019-10-31

7.  Trojan Horse Delivery of 4,4'-Dimethoxychalcone for Parkinsonian Neuroprotection.

Authors:  Wenlong Zhang; Huaqing Chen; Liuyan Ding; Junwei Gong; Mengran Zhang; Wenyuan Guo; Pingyi Xu; Shiying Li; Yunlong Zhang
Journal:  Adv Sci (Weinh)       Date:  2021-03-03       Impact factor: 16.806

8.  Dose-dependent effect of mesenchymal stromal cells co-grafted with dopaminergic neurons in a Parkinson's disease rat model.

Authors:  Jannette Rodriguez-Pallares; Maria Garcia-Garrote; Juan A Parga; Jose Luis Labandeira-Garcia
Journal:  J Cell Mol Med       Date:  2021-09-18       Impact factor: 5.310

Review 9.  Transcranial Current Stimulation as a Tool of Neuromodulation of Cognitive Functions in Parkinson's Disease.

Authors:  Ivan V Brak; Elena Filimonova; Oleg Zakhariya; Rustam Khasanov; Ivan Stepanyan
Journal:  Front Neurosci       Date:  2022-07-12       Impact factor: 5.152

Review 10.  Neuronal Replacement as a Tool for Basal Ganglia Circuitry Repair: 40 Years in Perspective.

Authors:  Anders Björklund; Malin Parmar
Journal:  Front Cell Neurosci       Date:  2020-05-29       Impact factor: 5.505

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.